iHuman (IH) Resumen de Acciones

iHuman Inc. suministra productos de desarrollo intelectual a usuarios particulares, guarderías y distribuidores en la República Popular China y a escala internacional. Saber más

Análisis fundamental de IH
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	3/6
Salud financiera	6/6
Dividendos	3/6

Recompensas

El ratio precio-beneficios (6.1x) es inferior al del mercado US (19.2x)

Análisis de riesgos

No tiene una capitalización de mercado significativa ($86M)

IH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Media opportunity

Eva Live

Fair Value from

Ceazar

US$7.4351.5% infravalorado

Is this the AI replacing marketing professionals?

Key Takeaways EVA Live (Nasdaq:GOAI) has launched NeuroServer , a purpose-built AI system trained specifically for digital advertising rather than built on off-the-shelf AI models. Its custom neural architecture is designed for multi-objective optimisation across real campaign KPIs, and was trained using reinforcement learning in an agency environment, positioning it very differently from typical AI-powered ad-tech tools.

Read narrative

Competidores de iHuman Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del iHuman
Precios históricos de las acciones
Precio actual de la acción	US$1.68
Máximo en las últimas 52 semanas	US$3.60
Mínimo de 52 semanas	US$1.55
Beta	0.12
Cambio en 1 mes	-0.30%
Variación en 3 meses	-16.25%
Cambio de 1 año	-30.78%
Variación en 3 años	-55.09%
Variación en 5 años	-82.48%
Variación desde la OPV	-89.53%

Noticias y actualizaciones recientes

Artículo de análisis • Feb 12

iHuman (NYSE:IH) Is Reinvesting At Lower Rates Of Return

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

Artículo de análisis • Dec 31

Take Care Before Jumping Onto iHuman Inc. (NYSE:IH) Even Though It's 26% Cheaper

The iHuman Inc. ( NYSE:IH ) share price has fared very poorly over the last month, falling by a substantial 26...

Recent updates

Artículo de análisis • Feb 12

iHuman (NYSE:IH) Is Reinvesting At Lower Rates Of Return

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

Artículo de análisis • Dec 31

Take Care Before Jumping Onto iHuman Inc. (NYSE:IH) Even Though It's 26% Cheaper

The iHuman Inc. ( NYSE:IH ) share price has fared very poorly over the last month, falling by a substantial 26...

Artículo de análisis • Jul 25

iHuman Inc.'s (NYSE:IH) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

iHuman Inc. ( NYSE:IH ) shares have continued their recent momentum with a 27% gain in the last month alone. The last...

Artículo de análisis • Jul 23

A Look At The Intrinsic Value Of iHuman Inc. (NYSE:IH)

Key Insights iHuman's estimated fair value is US$2.45 based on 2 Stage Free Cash Flow to Equity iHuman's US$2.79 share...

Artículo de análisis • Apr 14

Investors Don't See Light At End Of iHuman Inc.'s (NYSE:IH) Tunnel And Push Stock Down 38%

iHuman Inc. ( NYSE:IH ) shares have retraced a considerable 38% in the last month, reversing a fair amount of their...

Artículo de análisis • Feb 28

Improved Earnings Required Before iHuman Inc. (NYSE:IH) Stock's 27% Jump Looks Justified

iHuman Inc. ( NYSE:IH ) shareholders have had their patience rewarded with a 27% share price jump in the last month...

Artículo de análisis • Sep 28

There's No Escaping iHuman Inc.'s (NYSE:IH) Muted Earnings Despite A 27% Share Price Rise

iHuman Inc. ( NYSE:IH ) shareholders would be excited to see that the share price has had a great month, posting a 27...

Artículo de análisis • May 21

iHuman Inc.'s (NYSE:IH) Share Price Is Matching Sentiment Around Its Earnings

iHuman Inc.'s ( NYSE:IH ) price-to-earnings (or "P/E") ratio of 4.3x might make it look like a strong buy right now...

Artículo de análisis • Jan 30

Some Investors May Be Worried About iHuman's (NYSE:IH) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...

Artículo de análisis • Dec 30

iHuman Inc.'s (NYSE:IH) Business And Shares Still Trailing The Market

With a price-to-earnings (or "P/E") ratio of 6.3x iHuman Inc. ( NYSE:IH ) may be sending very bullish signals at the...

Artículo de análisis • Oct 13

Why We Like The Returns At iHuman (NYSE:IH)

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

Seeking Alpha • Sep 26

iHuman Moves Through Economic Uncertainty In Robotic Holding Pattern

Summary The provider of educational products and services for children reported just 4.5% revenue growth in the second quarter, but its profit nearly doubled on reduced R&D spending. iHuman’s revenue grew by an unimpressive 4.5% in the second quarter, but it maintained its margins and reported strong profit growth on cost controls. The education company’s deferred revenue declined for a second consecutive quarter from a peak at the end of last year. Read the full article on Seeking Alpha

Artículo de análisis • Jul 29

iHuman Inc.'s (NYSE:IH) 26% Share Price Surge Not Quite Adding Up

iHuman Inc. ( NYSE:IH ) shares have had a really impressive month, gaining 26% after a shaky period beforehand. The...

Seeking Alpha • Jun 23

iHuman Leaves Investors Unimpressed With Flat Margins, Slow Revenue Growth

Summary iHuman Inc. reported its revenue grew 9% in the first quarter. IH's profit quadrupled as it controlled costs with a sharp drop in R&D spending. iHuman has launched two new initiatives over the last year to tap the international market, but has yet to record significant revenue from those. IH just needs to start reaping some rewards from its efforts with a return to faster revenue growth. Read the full article on Seeking Alpha

Seeking Alpha • Dec 14

Operating In The Shadows Of Education Crackdown, iHuman Nears Profit Milestone

Summary iHuman made a net profit in the third quarter, swinging from a loss a year earlier, as cost savings outweighed a decline in revenue. The company faces a long list of regulatory risks, led by the educational nature of its apps that could subject them to more stringent rules. iHuman says its apps are not explicitly subject to these rules. But it also warns that Chinese regulators could decide at any time that its apps are for educational purposes, which would bring the company lots of headaches. A major milestone is in sight for iHuman Inc. (IH) as it nears its first annual net profit in its life as a young publicly traded company. But in the process of reaching that goal, the maker of “edutainment” apps is having to constantly navigate a regulatory minefield in China’s sensitive education sector that could upend its business at any time. A major mine from that field blew up in the face of a much larger industry providing after-school tutoring services to K-12 students last year after Beijing suddenly banned most such services. iHuman has avoided fallout from that fiasco, which effectively killed an entire industry once worth billions of dollars. But the dangers always lurk in the background due to the fickle and unpredictable nature of China’s regulators. iHuman, which makes apps that help kids improve in areas like reading and logic, made a net profit of 39.5 million yuan ($5.5 million) in the third quarter, pulling a 180-degree turn from a net loss of a similar size a year earlier, according to its latest quarterly results released last Thursday. Those results showed the company earned a 74 million yuan profit for the first nine months of the year, putting iHuman on track to make its first-ever annual net profit since it went public in 2020. iHuman’s strong third quarter bottom line owes in large part to cost-cutting, rather than revenue growth. In fact, the company’s sales during the three months fell 2.9% year-over-year to 251.5 million yuan, marking the first decline in its quarterly revenue since its IPO. The decline was a natural progression from lackluster growth in the first half of the year, a far cry from the triple-digit growth that it frequently logged in the past two years. The sudden drop in iHuman’s revenue may seem perplexing, if not alarming. It’s true that many businesses in China suffered under Beijing’s strict Covid control policies that only now are starting to ease, though not before contributing to the country’s economic slowdown. If anything, internet companies like iHuman should be key beneficiaries of lockdowns and other restrictions on mobility that have fueled growth in demand for online products that don’t require human contact. iHuman also sells cognitive development materials and devices through brick-and-mortar channels. But it has drastically scaled down the offline business, which led to significant gains in its gross margin and allowed it to keep boosting revenue through the pandemic. So, what exactly is behind iHuman’s slowdown? It actually appears to be the result of a conscious decision by the company to prioritize profitability over revenue growth. Firstly, the company’s cost of revenue - or expenses incurred for generating sales, including commissions to app stores - decreased at a faster rate than its revenue decline. That allowed iHuman to further improve its gross margin to more than 70% from an already-solid 69.6% in the third quarter of last year. Slashing costs More significantly, iHuman slashed its operating expenses, which in the past exceeded its gross profit, by more than 38%. Cost cutting has become a common theme among money-losing Chinese companies this year, as they try to show investors they can become profitable soon, even in the face of a fast-slowing Chinese economy. iHuman’s cuts were led by a 45% drop in costs for research and development, primarily through savings from payroll and outsourcing expenses. It also reduced sales and marketing expenses by 38% by using an “economical and optimized advertising strategy.” “The continued improvement in profitability was primarily driven by our sound operating efficiency initiatives,” iHuman CFO Vivien Wang said in the company’s latest earnings announcement. “We better aligned our cost structure with our strategic priorities and improved our operational efficiency by further streamlining key business processes and workflows.” Investors appeared to appreciate iHuman’s renewed focus on profitability, as well as its previously announced plan to repurchase its shares through the end of next year. The company’s stock dropped about 7% after its earnings release, but more than made up the lost ground the next day with a 12.4% jump. While the short-term picture looks good, iHuman faces a wide range of longer-term risks due to its operation in a vast regulatory gray area in China. The company describes itself as an “edutainment” provider and seems to try hard not to link its apps directly to the sensitive education sector, which is subject to a long list of regulatory requirements. Following last year’s clampdown on the sector, even overseas language-learning apps like Duolingo (DUOL), Memrise and Beelinguapp have vanished from major Android app stores in China. iHuman says its apps are not explicitly subject to these rules. But it also warns that Chinese regulators could decide at any time that its apps are for educational purposes, which would bring the company lots of headaches. There are also a slew of other rules that could apply to iHuman, ranging from requirements for online publishing to those for protection of minors from addictive products.

Artículo de análisis • Dec 09

iHuman (NYSE:IH) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Seeking Alpha • Dec 08

iHuman ADS Non-GAAP EPADS of $0.11, revenue of $35.4M

iHuman ADS press release (NYSE:IH): Q3 Non-GAAP EPADS of $0.11. Revenue of $35.4M (-2.9% Y/Y). Gross margin was 70.4%, compared with 69.6% in the same period last year. Average total MAUs for the quarter were 20.63M, an increase of 16.7% Y/Y from 17.68M in the same period last year. The number of paying users for the quarter was 1.65M.

Seeking Alpha • Oct 03

iHuman Is Inhumanly Undervalued

Summary iHuman is the education app leader in the world's largest app market. The company had its most profitable quarter ever, while its enterprise value remains negative. In July, iHuman's international STEM apps brand was launched and existing popular apps were released in Google Play stores worldwide. Editor's note: Seeking Alpha is proud to welcome The China Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » iHuman's (NYSE:IH) share price has declined by more than 90% since its peak of around $28 in November 2020, to less than $1.90 recently. This has resulted in iHuman's enterprise value turning negative while fundamentals have been improving. iHuman's negative enterprise value is mainly due to a combination of high cash reserves, low debt, and a low market cap. Net income performance has been improving for the past three quarters and is now at record levels, while operating expenses have declined dramatically and are now near two-year lows. Seekingalpha The market has also not priced in the launch of internationally focused brand Bekids and the release of existing popular apps in Google Play stores globally. iHuman's price to sales ratio of 0.7 is less than 10% of Duolingo's (DUOL), a listed competing educational app maker. The market has also heavily discounted the fact that iHuman is the educational app leader in one of the world's fastest growing and largest app markets. As iHuman continues to be profitable and gather more attention, its stock price should rise. Therefore, I rate this stock a buy. Business Model iHuman makes educational apps for children. These apps span many categories, including reading, Chinese language learning, coding, and more. Revenue is primarily derived from subscriptions to these apps, although a one-time lifetime access purchase is also available. iHuman Chinese is iHuman's flagship product. It was launched in 2016 and, in 2021, generated 65% of all revenue. The 2021 annual report revealed that most of iHuman's revenue is generated in China. On Sensortower, an app intelligence platform, it can be seen that iHuman apps are highly rated. In the Chinese Apple app store, iHuman Chinese has an average rating of 4.8 across more than 830,000 reviews. The lowest rated iHuman app is iHuman Exercise, which received an average rating of 4.1 across 235 reviews. Market and developments As the market leader in China's education app industry, iHuman is well positioned to reap rewards from growth in China's app industry. China's app market, already the largest in the world, is projected to grow at a CAGR of 9.65% to reach a revenue of USD$226 billion in 2026. This is almost 50% larger than second-placed U.S., whose app market is projected to generate a revenue of USD$151 billion in 2026. Category specific trends are even more positive, as demand for education apps and language learning apps is expected to grow at CAGRs of 24% and 15% in 2022-2027, respectively. In July 2022, iHuman launched the Bekids suite of apps targeting the children's STEM market. Bekids Coding is an international port of the popular iHuman Coding, and will be the primary app in the Bekids suite. Also in July, iHuman's most popular apps - such as iHuman Chinese and iHuman PinYin (launched as GoPlay Chinese) - were released in Google Play stores internationally. These initiatives are expected to further drive international revenue. KPIs iHuman app KPIs have been improving since its IPO. On a yearly basis, monthly active users (MAUs) and paying users (PUs) have continued to climb, reaching 18.2 million and 1.51 million, respectively. Average revenue per paying user also increased year on year, climbing 2.1% to USD$21. In the China Apple app store, the iHuman flagship product, iHuman Chinese, is the undisputed champion in the education category. According to Chinese app intelligence company Qimai data, iHuman Chinese ranked within the top 10 grossing applications in the past five years, and held the top grossing education app crown for the same period of time. Financial Analysis Koyfin In Q2 2022, iHuman made the most net income ever, growing 66% on a quarterly basis to USD$3.3 million. Net margin improved for the third quarter in a row to 9.45%. This improvement in net margin was not the result of an increase in revenue though, as revenue was mostly unchanged at USD$34.4 million. Instead, the improvement in net margin was the result of sharp cuts to R&D and sales and marketing expenses. Author On a quarterly basis, R&D expenses decreased substantially to USD$11.7 million, while sales and marketing expenses decreased to USD$4.7 million. Compared to other listed app makers such as Roblox (RBLX) and Duolingo, iHuman's operating expenses as a percentage of revenue are lower, suggesting that the company is more efficient at managing costs. Gross margins have consistently remained at around 70%, suggesting that there is plenty of room for iHuman to be profitable. IH's balance sheet is healthy with cash of USD$127 million while total debt is only USD$2.7 million. The largest liability item is deferred revenue, at USD$47 million. My only concern is that there is more than enough cash to sustain the business for many years and that this has been the case for many quarters now. Like many other Chinese ADRs, IH's large cash holdings and low market cap have resulted in a negative enterprise value. Valuation To value iHuman, we will compare it to language learning app Duolingo. This is an appropriate comparison because both companies are listed app makers whose apps are in the education category of app stores. According to Sensortower, in the top grossing education app category, Duolingo was ranked 1st and 10th in U.S. and Chinese app stores, respectively. Duolingo has had a longer runway than iHuman, though, as its apps were released in 2012 vs. 2016 for iHuman's earliest app, iHuman Chinese. Seekingalpha On a TTM basis, Duolingo generated a net income loss of USD$74 million on a revenue of USD$306 million, while iHuman generated a net income loss of USD$1.67 million on a revenue of USD$145 million. Duolingo's revenue is more than twice that of iHuman's, but that would not be obvious by looking at their price/sales ratios. Duolingo's price/sales ratio is more than 10, whereas iHuman's is 0.7. This suggests that there is a possibility of a large upside if iHuman's price/sales ratio converges to even half that of Duolingo's. Risks Delisting On May 26, iHuman was included in the HFCAA's conclusive list of issuers, raising delisting fears. While Washington and Beijing have since reached an agreement allowing U.S. auditors to inspect China-based accountants, there remains a possibility that the inspection might fail and the ADR gets delisted. To avoid this scenario, it is quite likely that iHuman will follow in the path of other Chinese ADRs, such as NIO and Li Auto, and pursue a listing on the Hong Kong stock exchange.

Seeking Alpha • Sep 22

iHuman ADS GAAP EPS of $0.07, revenue of $34.4M

iHuman ADS press release (NYSE:IH): Q2 GAAP EPS of $0.07. Revenue of $34.4M (+4.2% Y/Y)

Artículo de análisis • Jun 09

Is iHuman Inc. (NYSE:IH) Trading At A 34% Discount?

In this article we are going to estimate the intrinsic value of iHuman Inc. ( NYSE:IH ) by taking the forecast future...

Artículo de análisis • May 02

Analysts Expect iHuman Inc. (NYSE:IH) To Breakeven Soon

We feel now is a pretty good time to analyse iHuman Inc.'s ( NYSE:IH ) business as it appears the company may be on the...

Artículo de análisis • Feb 28

What Type Of Shareholders Make Up iHuman Inc.'s (NYSE:IH) Share Registry?

The big shareholder groups in iHuman Inc. ( NYSE:IH ) have power over the company. Institutions often own shares in...

Rentabilidad de los accionistas

	IH	US Entertainment	Mercado US
7D	-3.2%	-1.0%	2.2%
1Y	-30.8%	-9.3%	31.1%

Rentabilidad vs. Industria: Los resultados de IH fueron inferiores a los de la industria US Entertainment, que obtuvo un rendimiento del -9.3% el año pasado.

Rentabilidad vs. Mercado: IH obtuvo unos resultados inferiores a los del mercado US, que fueron del 31.1% el año pasado.

Volatilidad de los precios

Is IH's price volatile compared to industry and market?
IH volatility
IH Average Weekly Movement	7.7%
Entertainment Industry Average Movement	9.0%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Precio estable de las acciones: IH no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IH (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1996	558	Peng Dai	www.ihuman.com

iHuman Inc. ofrece productos de desarrollo intelectual a usuarios particulares, guarderías y distribuidores en la República Popular China y a escala internacional. La empresa ofrece aplicaciones interactivas y autodidactas, como iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Chinese Classics, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Readers, iHuman Writing, iHuman Fantastic Friends, iHuman AI Coding y iHuman Chinese Reading; las series bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy y Gogo; y Aha World y Aha Makeover. También proporciona materiales intelectualmente estimulantes, incluidos libros, materiales interactivos y dispositivos inteligentes que desarrollan las capacidades de los niños en expresión oral, pensamiento crítico, lectura independiente y creatividad; y Cosmicrew, una serie de animación de aventuras cómicas en 3D.

Resumen de fundamentos de iHuman Inc.

¿Cómo se comparan los beneficios e ingresos de iHuman con su capitalización de mercado?
Estadísticas fundamentales de IH
Capitalización bursátil	US$85.61m
Beneficios(TTM)	US$14.03m
Ingresos (TTM)	US$118.67m

6.1x

Ratio precio-beneficio (PE)

0.7x

Ratio precio-ventas (PS)

¿Está IH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IH
Ingresos	CN¥807.02m
Coste de los ingresos	CN¥259.41m
Beneficio bruto	CN¥547.61m
Otros gastos	CN¥452.21m
Beneficios	CN¥95.40m

Últimos beneficios comunicados

Dec 31, 2025

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	1.87
Margen bruto	67.86%
Margen de beneficio neto	11.82%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IH a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

6.0%

Rentabilidad actual por dividendo

n/a

Ratio de pagos

¿Paga IH dividendos fiables?

Ver historial de dividendos e índices de referencia de IH

¿Cuándo hay que comprar IH para recibir un próximo dividendo?
fechas de dividendos de iHuman
Fecha ex dividendo	Apr 17 2026
Fecha de pago de dividendos	May 15 2026
Días hasta ex dividendo	24 days
Días hasta la fecha de pago de dividendos	4 days

¿Paga IH dividendos fiables?

Ver historial de dividendos e índices de referencia de IH

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/11 07:08
Precio de las acciones al final del día	2026/05/08 00:00
Beneficios	2025/12/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

iHuman Inc. está cubierta por 4 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Citi Research	Citigroup Inc
Mark Li	Citigroup Inc
Mark Li	Citigroup Inc

iHuman (IH) Resumen de Acciones

Recompensas

Análisis de riesgos

Is this the AI replacing marketing professionals?

Competidores de iHuman Inc.

GCL Global Holdings

Gamehaus Holdings

CTW Cayman

GDEV

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Upcoming dividend of US$0.085 per share

Full year 2025 earnings released: EPS: CN¥1.87 (vs CN¥1.88 in FY 2024)

ihuman Inc. Approves A Special Cash Dividend, Payable on or Around May 8, 2026 and May 15, 2026

iHuman (NYSE:IH) Is Reinvesting At Lower Rates Of Return

Now 22% undervalued after recent price drop

Take Care Before Jumping Onto iHuman Inc. (NYSE:IH) Even Though It's 26% Cheaper

Recent updates

Upcoming dividend of US$0.085 per share

Full year 2025 earnings released: EPS: CN¥1.87 (vs CN¥1.88 in FY 2024)

ihuman Inc. Approves A Special Cash Dividend, Payable on or Around May 8, 2026 and May 15, 2026

iHuman (NYSE:IH) Is Reinvesting At Lower Rates Of Return

Now 22% undervalued after recent price drop

Take Care Before Jumping Onto iHuman Inc. (NYSE:IH) Even Though It's 26% Cheaper

Third quarter 2025 earnings released: EPS: CN¥0.42 (vs CN¥0.48 in 3Q 2024)

Investor sentiment deteriorates as stock falls 16%

Second quarter 2025 earnings released: EPS: CN¥0.62 (vs CN¥0.47 in 2Q 2024)

Now 21% overvalued after recent price rise

New minor risk - Share price stability

iHuman Inc.'s (NYSE:IH) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

A Look At The Intrinsic Value Of iHuman Inc. (NYSE:IH)

Now 25% overvalued after recent price rise

First quarter 2025 earnings released: EPS: CN¥0.52 (vs CN¥0.42 in 1Q 2024)

Investor sentiment improves as stock rises 20%

Investors Don't See Light At End Of iHuman Inc.'s (NYSE:IH) Tunnel And Push Stock Down 38%

Upcoming dividend of US$0.085 per share

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Full year 2024 earnings released: EPS: CN¥9.41 (vs CN¥3.43 in FY 2023)

Ihuman Inc. Approves A Special Cash Dividend, Payable on or around May 8, 2025

New minor risk - Share price stability

Investor sentiment improves as stock rises 21%

Improved Earnings Required Before iHuman Inc. (NYSE:IH) Stock's 27% Jump Looks Justified

Third quarter 2024 earnings released: EPS: CN¥2.40 (vs CN¥0.98 in 3Q 2023)

There's No Escaping iHuman Inc.'s (NYSE:IH) Muted Earnings Despite A 27% Share Price Rise

Second quarter 2024 earnings released: EPS: CN¥0.47 (vs CN¥0.80 in 2Q 2023)

First quarter 2024 earnings released: EPS: CN¥2.12 (vs CN¥1.01 in 1Q 2023)

iHuman Inc.'s (NYSE:IH) Share Price Is Matching Sentiment Around Its Earnings

Full year 2023 earnings released: EPS: CN¥3.43 (vs CN¥2.06 in FY 2022)

Ihuman Inc. Approves Special Cash Dividend, Payable on or Around May 8, 2024 and May 15, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

Some Investors May Be Worried About iHuman's (NYSE:IH) Returns On Capital

iHuman Inc.'s (NYSE:IH) Business And Shares Still Trailing The Market

Third quarter 2023 earnings released: EPS: CN¥4.92 (vs CN¥0.74 in 3Q 2022)

Why We Like The Returns At iHuman (NYSE:IH)

iHuman Moves Through Economic Uncertainty In Robotic Holding Pattern

Second quarter 2023 earnings released: EPS: CN¥3.98 (vs CN¥0.41 in 2Q 2022)

iHuman Inc.'s (NYSE:IH) 26% Share Price Surge Not Quite Adding Up

iHuman Leaves Investors Unimpressed With Flat Margins, Slow Revenue Growth

First quarter 2023 earnings released: EPS: CN¥1.01 (vs CN¥0.24 in 1Q 2022)

Investor sentiment deteriorates as stock falls 18%

Now 20% undervalued

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥2.06 (vs CN¥0.69 loss in FY 2021)

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 24%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Operating In The Shadows Of Education Crackdown, iHuman Nears Profit Milestone

iHuman (NYSE:IH) May Have Issues Allocating Its Capital

Third quarter 2022 earnings released: EPS: CN¥3.71 (vs CN¥0.72 loss in 3Q 2021)

iHuman ADS Non-GAAP EPADS of $0.11, revenue of $35.4M

Less than half of directors are independent

iHuman Is Inhumanly Undervalued

Second quarter 2022 earnings released

iHuman ADS GAAP EPS of $0.07, revenue of $34.4M

First quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.13 in 1Q 2021)

Less than half of directors are independent